Dahlberg agrees to pay record sum for deceptive advertising
This article was originally published in Clinica
Bausch & Lomb subsidiary Dahlberg has agreed to pay a record $2.75 million for advertising claims it made after the Federal Trade Commission told the company that they were deceptive and Dahlberg should stop using them. The company had claimed its Miracle Ear Clarifier Hearing Aids could block out background noise, amplifying only speech. The FTC said the devices could not.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.